Detection of recurrent cervical cancer by whole-body FDG PET scan in asymptomatic and symptomatic-women

被引:66
作者
Unger, JB
Ivy, JJ
Connor, P
Charrier, A
Ramaswamy, MR
Ampil, FL
Monsour, RP
机构
[1] Louisiana State Univ, Div Gynecol Pelv Surg, Dept Obstet & Gynecol, Hlth Sci Ctr, Shreveport, LA 71130 USA
[2] Louisiana State Univ, PET Imaging Ctr, Biomed Res Fdn NW Louisiana, Hlth Sci Ctr, Shreveport, LA 71130 USA
[3] Louisiana State Univ, Div Radiat Oncol, Hlth Sci Ctr, Shreveport, LA 71130 USA
[4] Louisiana State Univ, Div Hematol Oncol, Hlth Sci Ctr, Shreveport, LA 71130 USA
关键词
FDG PET scan; recurrent cervical cancer;
D O I
10.1016/j.ygyno.2004.04.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. To determine the ability of whole-body [F-18]fluoro-2-deoxyglucose (FDG) positron emission tomography (PET) scan to detect recurrent cervical carcinoma in both symptomatic and asymptomatic women. Materials and methods. We retrospectively reviewed the records of 44 women previously treated for cervical cancer who underwent 47 posttreatment whole-body FDG PET scans in an attempt to detect recurrent disease. Twenty-six scans were performed in asymptomatic women, whereas 21 scans were performed in women with symptoms suggestive of recurrence. Results. About 30.8% of asymptomatic women had recurrent disease detected by PET scan compared to 66.7% of women in the symptomatic group. The sensitivity of PET scan for recurrent disease in asymptomatic women was 80.0%, specificity of 100%, a positive predictive value of 100%, and a negative predictive value of 88.9%. For symptomatic women, the sensitivity of PET was 100%, specificity of 85.7%, a positive predictive value of 93.3%, and a negative predictive value of 100%. Conclusions. The whole-body FDG PET scan is a sensitive imaging modality for the detection of recurrent cervical carcinoma in both symptomatic and asymptomatic women. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:212 / 216
页数:5
相关论文
共 12 条
[1]   Posttherapy surveillance of women with cervical cancer: An outcomes analysis [J].
Bodurka-Bevers, D ;
Morris, M ;
Eifel, PJ ;
Levenback, C ;
Bevers, MW ;
Lucas, KR ;
Wharton, JT .
GYNECOLOGIC ONCOLOGY, 2000, 78 (02) :187-193
[2]   Posttherapy surveillance monitoring of cervical cancer by FDG-pet [J].
Grigsby, PW ;
Siegel, BA ;
Dehdashti, F ;
Mutch, DG .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 55 (04) :907-913
[3]   Lymph node staging by positron emission tomography in patients with carcinoma of the cervix [J].
Grigsby, PW ;
Siegel, BA ;
Dehdashti, F .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (17) :3745-3749
[4]   The role of PET scanning in the detection of recurrent cervical cancer [J].
Havrilesky, LJ ;
Wong, TZ ;
Secord, AA ;
Berchuck, A ;
Clarke-Pearson, DL ;
Jones, EL .
GYNECOLOGIC ONCOLOGY, 2003, 90 (01) :186-190
[5]   A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: Potential impact on treatment [J].
Narayan, K ;
Hicks, RJ ;
Jobling, T ;
Bernshaw, D ;
McKenzie, AF .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2001, 11 (04) :263-271
[6]   Metastatic lymph nodes in patients with cervical cancer:: Detection with MR imaging and FDG PET [J].
Reinhardt, MJ ;
Ehritt-Braun, C ;
Vogelgesang, D ;
Ihling, C ;
Högerle, S ;
Mix, M ;
Moser, E ;
Krause, TM .
RADIOLOGY, 2001, 218 (03) :776-782
[7]  
SHEPHERD JH, 1995, INT J GYNECOL CANCER, V5, P319
[8]  
SOISSON AP, 1990, OBSTET GYNECOL, V76, P106
[9]  
Sugawara Y, 1999, J NUCL MED, V40, P1125
[10]  
Sun SS, 2001, ANTICANCER RES, V21, P2957